Can-Fite BioPharma American Depositary Shares
CANF
12 hedge funds and large institutions have $186K invested in Can-Fite BioPharma American Depositary Shares in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
10.5% less ownership
Funds ownership: 12.37% → 1.88% (-10%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
94% less capital inflows, than outflows
Capital inflows: $78.1K | Capital outflows: $1.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$51.1K |
| 2 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$20.2K |
| 3 |
Kohmann Bosshard Financial Services
Fairlawn,
Ohio
|
+$6.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$1.31M |
| 2 |
Morgan Stanley
New York
|
-$36.8K |
| 3 |
Two Sigma Securities
New York
|
-$20.6K |
CANF Hedge Fund Activity: Q4 2024 in Review
12 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q4 2024, worth a combined $186K — down 88% from $1.52M a quarter earlier.
Fund positioning in CANF was balanced in Q4 2024: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $51.1K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.31M sold.
- 12 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $186K of Can-Fite BioPharma American Depositary Shares stock for Q4 2024, down 88% quarter-over-quarter.
- 2 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q4 2024 and 2 closed out, a net change of 0 holders.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q4 2024 was BNP Paribas Financial Markets, an estimated $51.1K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q4 2024 was Armistice Capital, an estimated $1.31M sold.
Based on aggregated 13F filings for Q4 2024.